This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says

Earlier this week, vTv Therapeutics Inc VTVT named a new CEO, Paul Sekhri, and announced the progress with the initiation of pivotal TTP399 trials.
TTP399 is a novel, oral, liver-selective glucokinase activator that has FDA Breakthrough Therapy Designation for type 1 diabetes.
Phase 2 study previously demonstrated approximately 40% reduction of hypoglycemic episodes with once-daily doses of TTP399 compared to placebo.
Also Read: vTv Therapeutics Shares Jump On Equity Investment.
Currently, vTv is planning two pivotal, placebo-controlled clinical trials with TTP399 in subjects with T1D (n=1,000), with at least one of the studies expected to treat patients for a year.
HC Wainwright believes TTP399 targets a significant market opportunity given that there are no approved therapies for reducing hypoglycemic episodes.
The analysts estimate approximately 1.6 million people with T1D in the U.S. and about 26 million with T1D globally.
Since TPP399 has a benign safety profile, TTP399 could realize more than $1 billion in annual sales as an adjunctive treatment to insulin, using just 10% of T1D patients, HC Wainwright writes.
The analyst reiterates the Buy rating and the price target of $6.
Price Action: VTVT shares are down 0.80% at $1.21 on the last check Thursday.

Analyst Calendar